Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Priority review for macular degeneration therapy:

This article was originally published in Clinica

Executive Summary

The US FDA has granted priority review status to Coherent Medical's combined laser and drug treatment for the wet form of age-related macular degeneration, a leading cause of blindness in people over the age of 50 in the western world. Visudyne therapy uses the company's OPAL photoactivator laser with the drug verteporferin. It was submitted to the agency as a joint device/drug application by Coherent and QLT PhotoTherapeutics. Priority status indicates that the FDA will review the application for approval within six months, said Santa Barbara, California-based Coherent.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel